Trevi Therapeutics detailed a Series B financing of According to a release, TPG Biotech previously invested
The Company plans to use the funding for the initiation of pivotal trials in two severe itch conditions: uremic pruritus and prurigo nodularis. The Company recently released data from its successfully completed Phase 1 trial in which Nalbuphine ER was shown to be well tolerated in patients on hemodialysis with itch and established proof-of-concept in uremic pruritus. The Company intends to initiate both pivotal trials in the third quarter of this year, and expects to have top-line results in the second half of 2015.
Trevi Therapeutics is a clinical stage biotechnology company focused on developing Nalbuphine ER for chronic pruritus (itch).
More information and complete details:
((Comments on this story may be sent to firstname.lastname@example.org))
Trevi Therapeutics detailed a Series B financing of
According to a release, TPG Biotech previously invested